Multiple Sclerosis
Clemastine fumarate linked to accelerated disability progression in MS
WEST PALM BEACH, Fla. — Treatment with clemastine fumarate was linked to accelerated disease and disability progression due to pyroptosis in a small cohort of individuals with multiple sclerosis, according to a presenter at ACTRIMS 2024.
FDA grants breakthrough designation to vagus nerve stimulation device
The FDA has approved breakthrough device designation for a novel neuroimmune modulation platform for those with relapsing-remitting multiple sclerosis, according to the manufacturer.
Evobrutinib nonsuperior to teriflunomide for relapsing forms of MS
WEST PALM BEACH, Fla. — Treatment with evobrutinib was nonsuperior to teriflunomide in confirmed disability progression at 12 and 24 weeks for those with relapsing forms of multiple sclerosis, according to a presenter at ACTRIMS 2024.
‘Wearing off’ monoclonal antibodies leads to patient dissatisfaction, depression in MS
WEST PALM BEACH, Fla. — The “wearing-off” effect with monoclonal antibodies prescribed for multiple sclerosis led to treatment dissatisfaction and was associated with depression, according to a poster from ACTRIMS 2024.
Patient-recorded home video feasible method to assess gait kinematics in MS
WEST PALM BEACH, Fla. — In-home video taken by adults with multiple sclerosis is a feasible and valid method to determine the mechanism and motion of their gait, according to a poster from ACTRIMS 2024.
Speech pauses in multiple sclerosis may indicate cognitive impairment
WEST PALM BEACH, Fla. — Variability and length of pauses in speech may indicate cognitive impairment for German-speaking individuals with multiple sclerosis, according to a poster from ACTRIMS 2024.
Neoadjuvant immunotherapy may improve sarcoma outcomes
A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the safety and potential efficacy of neoadjuvant immunotherapy for patients with soft tissue sarcoma.
Uplizna linked to improved outcomes for Hispanic/Latino patients with NMOSD
WEST PALM BEACH, Fla. — Hispanic and Latino individuals with neuromyelitis optica spectrum disorder experienced improved outcomes with Uplizna compared with placebo, according to a poster from ACTRIMS 2024.
Survey reveals disparities in MS knowledge, care among physicians
WEST PALM BEACH, Fla. — Among residents and attending physicians at an Ivy League medical center, disparities exist in knowledge and understanding of care for those with multiple sclerosis, according to a poster from ACTRIMS 2024.
No correlation found between depression, self-reported disability in MS
WEST PALM BEACH, Fla. — No correlation was found between depression and self-report of disability in a small group of patients with multiple sclerosis, according to a poster from ACTRIMS 2024.